FLUOROSCOPY X-RAY EQUIPMENT DOSE MONITORS RECOMMENDED BY FDA
This article was originally published in The Gray Sheet
Executive SummaryFLUOROSCOPY X-RAY EQUIPMENT DOSE MONITORS RECOMMENDED BY FDA to help prevent radiation overdoses during fluoroscopically-guided procedures, Bruce Burlington, director of FDA's Center for Devices and Radiological Health, told the annual meeting of the National Electrical Manufacturers Association's Diagnostic Imaging and Therapy Systems Division Sept. 19 in Edgartown, Massachusetts. FDA would like manufacturers to "incorporate equipment features which will monitor total delivered dose and make more practical the prevention of such injuries." The agency, however, currently is not planning on changing the x-ray performance standard to require dose monitors or other safety enhancements.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.